BOSTON, MA, May 11, 2017 /24-7PressRelease/
-- Andarix Pharmaceuticals, a clinical stage company, developing Tozaride, a targeted peptide therapy for small cell lung cancer announced that its Chief Executive Officer, Chris Adams, will present at the T3 Clinical Trials
Innovations Conference in Orlando, Florida May 11-12, 2017.
The presentation and panel discussion will highlight the growing role of digital health mobile and wearable technologies in patients living with cancer. The focus of the T3 conference is to demonstrate that harnessing new technologies in digital health leads to better patient engagement, care and management.
Tozaride is a novel, best-in-class therapy for lung and other cancers based on the radio-labeled somatostatin peptide Tozaride. Early clinical studies of Tozaride demonstrated that it is well tolerated and may produce prolonged stable disease and improved overall survival in heavily pre-treated advanced lung cancer patients. Tozaride targeted radiotherapy represents a new treatment paradigm which is expected to yield significant clinical benefit for both small cell lung cancer (SCLC), and non-small cell lung cancer (NSCLC) patients, and which will provide another treatment option for patients who are not eligible for, or who have not responded to current therapies.
About Andarix Pharmaceuticals
Andarix Pharmaceuticals is a clinical stage company developing targeted imaging and therapies for lung, neuroendocrine, and other cancers based on a proprietary somatostatin peptide conjugate. Extensive research has demonstrated that somatostatin receptors are highly up-regulated on several solid tumors, particularly lung cancers. Lung cancer is the leading cause of cancer mortality in the United States for both men and women. In 2016, there were an estimated 225,470 new diagnoses of non-small cell lung cancer (NSCLC) with 42,000 small cell lung cancer patients. To learn more about Andarix, please visit www.andarix.com